GLPwatch
Papers (10376)
Page 75 of 173, ranked by citation count.
- Cross-sectional, case-control and longitudinal associations between exposure to glucagon-like peptide-1 receptor agonists and the dispensing of antidepressants.
- Efficacy and safety of semaglutide in patients with heart failure with preserved ejection fraction and obesity.
- Cardiovascular outcome studies with incretin-based therapies: Comparison between DPP-4 inhibitors and GLP-1 receptor agonists.
- Exenatide Prevents Morphological and Structural Changes of Mitochondria Following Ischaemia-Reperfusion Injury.
- Exploring the potential impact of GLP-1 receptor agonists in cancer therapy.
- Semaglutide promotes the transition of microglia from M1 to M2 type to reduce brain inflammation in APP/PS1/tau mice.
- Metabolic outcomes of matched patient populations initiating exenatide BID vs. insulin glargine in an ambulatory care setting.
- Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial.
- Exendin-4 antagonizes the metabolic action of acylated ghrelinergic signaling in the hypothalamic paraventricular nucleus.
- Lixisenatide treatment for older patients with type 2 diabetes mellitus uncontrolled on oral antidiabetics: meta-analysis of five randomized controlled trials.
- The Use of Semaglutide in Patients With Renal Failure-A Retrospective Cohort Study.
- Liraglutide in adults with type 2 diabetes: global perspective on safety, efficacy and patient preference.
- Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL.
- Dulaglutide as an Add-on to Insulin in Type 2 Diabetes; Clinical Efficacy and Parameters Affecting the Response in Real-World Practice.
- Clinical Impact of Tirzepatide on Patients With OSA and Obesity.
- Glucagon-like peptide-1 receptor agonists and reduced mortality, cardiovascular and psychiatric risks in patients with psoriasis: a large-scale cohort study.
- Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) for type 2 diabetes in Spain based on real-world clinical evidence.
- Exendin-4, a glucagon-like peptide-1 analogue accelerates healing of chronic gastric ulcer in diabetic rats.
- Thermal stability of exenatide encapsulated in stratified dissolving microneedles during storage.
- Semaglutide Modulates Extracellular Matrix Production of LX-2 Cells via Exosomes and Improves Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
- Combination of ELISA and dried blood spot technique for the quantification of large molecules using exenatide as a model.
- Evaluating insulin secretagogues in a humanized mouse model with functional human islets.
- GLP-1R agonist may activate pancreatic stellate cells to induce rat pancreatic tissue lesion.
- Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes.
- Mapping in vivo microclimate pH distribution in exenatide-encapsulated PLGA microspheres.
- Euglycemic Ketoacidosis From Semaglutide in a Patient Without Diabetes.
- Liraglutide pharmacokinetics and exposure-response in adolescents with obesity.
- Cost-effectiveness and budget impact of liraglutide in type 2 diabetes patients with elevated cardiovascular risk: a US-managed care perspective.
- Effects of Dietary Self-Monitoring, Physical Activity, Liraglutide 3.0 mg, and Placebo on Weight Loss in the SCALE IBT Trial.
- Factors Affecting the Timing of Signal Detection of Adverse Drug Reactions.
- Hypothalamic obesity after craniopharyngioma surgery: Treatment with a long acting glucagon like peptide 1 derivated.
- A novel selective VPAC2 agonist peptide-conjugated chitosan modified selenium nanoparticles with enhanced anti-type 2 diabetes synergy effects.
- Glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes:real-world evidence from a Mediterranean area.
- Utilization of Anti-obesity Medications After Bariatric Surgery: Analysis of a Large National Database.
- Induction of apolipoprotein A-I gene expression by glucagon-like peptide-1 and exendin-4 in hepatocytes but not intestinal cells.
- Exenatide alleviates adriamycin-induced heart dysfunction in mice: Modulation of oxidative stress, apoptosis and inflammation.
- Liraglutide Treatment Ameliorates Neurotoxicity Induced by Stable Silencing of Pin1.
- The glucagon-like peptide 1 receptor agonist enhances intrinsic peroxisome proliferator-activated receptor γ activity in endothelial cells.
- The Potential Utility of Tirzepatide for the Management of Polycystic Ovary Syndrome.
- Effects of GLP-1 receptor agonists on asprosin levels in normal weight or overweight/obesity patients with type 2 diabetes mellitus.
- Clinical effectiveness of tirzepatide for patients with atrial fibrillation and type 2 diabetes: A retrospective cohort study.
- Safety and efficacy of liraglutide on reducing visceral and ectopic fat in adults with or without type 2 diabetes mellitus: A systematic review and meta-analysis.
- Exendin-4 protects murine pancreatic β-cells from dexamethasone-induced apoptosis through PKA and PI-3K signaling.
- Cardiovascular outcomes and safety with antidiabetic drugs.
- Incretin-Based Multi-Agonist Peptides Are Neuroprotective and Anti-Inflammatory in Cellular Models of Neurodegeneration.
- Semaglutide effects on energy balance are mediated by Adcyap1<sup>+</sup> neurons in the dorsal vagal complex.
- Fixed-ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin.
- IDegLira: Redefining insulin optimisation using a single injection in patients with type 2 diabetes.
- Biomaterial-Based Therapeutic Strategies for Obesity and Its Comorbidities.
- Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes--a protocol for a randomised, double-blind, placebo-controlled study: the Lira-1 study.
- GLP-1 receptor signaling restores aquaporin 4 subcellular polarization in reactive astrocytes and promotes amyloid β clearance in a mouse model of Alzheimer's disease.
- Lixisenatide Reduced Damage in Hippocampus CA1 Neurons in a Rat Model of Cerebral Ischemia-Reperfusion Possibly Via the ERK/P38 Signaling Pathway.
- Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States.
- Oral proniosomal amitriptyline and liraglutide for management of diabetic neuropathy: Exceptional control over hyperglycemia and neuropathic pain.
- Efficacy and Safety of Multiple Doses of Exenatide Once-Monthly Suspension in Patients With Type 2 Diabetes: A Phase II Randomized Clinical Trial.
- Weight loss and side-effects of liraglutide and lixisenatide in obesity and type 2 diabetes mellitus.
- A physiological role of glucagon-like peptide-1 receptors in the central nervous system of Suncus murinus (house musk shrew).
- Novel Site-Specific Fatty Chain-Modified GLP-1 Receptor Agonist with Potent Antidiabetic Effects.
- Optimization of Metformin in the GRADE Cohort: Effect on Glycemia and Body Weight.
- The short-term cost-effectiveness of once-daily liraglutide versus once-weekly exenatide for the treatment of type 2 diabetes mellitus in the United States.